BioGend Therapeutics Co., Ltd. (TPEX:6733)

BioGend Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	135.36	219.02	330.51	163.64	136.32	120.04
Short-Term Investments	450	400	393.76	329.76	552.96	392.99
Cash & Short-Term Investments	585.36	619.02	724.27	493.4	689.28	513.03
Cash Growth	-14.65%	-14.53%	46.79%	-28.42%	34.36%	38.74%
Accounts Receivable	50.15	47.36	26.69	11.27	5.05	0.28
Other Receivables	31.49	33.37	30.67	28.25	23.61	21.62
Receivables	81.64	80.72	57.36	39.52	28.66	21.89
Inventory	15.62	15.96	16.55	4.9	9.03	10.41
Prepaid Expenses	4.4	2	3	4.07	7.57	1.42
Total Current Assets	687.01	717.7	801.18	541.89	734.54	546.75
Property, Plant & Equipment	47.36	49.57	56.2	34.01	8.89	5.94
Long-Term Investments	8.52	8.33	20.34	10	-	69.43
Goodwill	17.09	17.09	17.09	17.09	17.09	-
Other Intangible Assets	103.4	114.07	151.04	210.95	261.92	102.29
Other Long-Term Assets	6.67	5.94	4.64	7.89	1.42	0.94
Total Assets	870.04	912.7	1,050	821.82	1,024	725.34
Accounts Payable	2.49	4.22	2.16	2.08	0.49	1.36
Accrued Expenses	18.94	20.61	16.57	17.22	14.39	14.19
Current Portion of Leases	3.51	3.59	3.65	3.49	3.94	-
Other Current Liabilities	2.42	4.81	23.87	9.07	6.3	2.72
Total Current Liabilities	27.35	33.23	46.25	31.86	25.13	18.27
Long-Term Leases	5.01	5.84	9.44	12.28	0.48	-
Long-Term Unearned Revenue	-	-	2.5	2.5	2.5	2.5
Long-Term Deferred Tax Liabilities	25.03	27.13	35.52	43.92	52.31	-
Total Liabilities	57.39	66.19	93.71	90.56	80.42	20.77
Common Stock	1,243	1,243	1,231	1,031	1,031	920
Additional Paid-In Capital	-	-	-	-	212.85	160.9
Retained Earnings	-431.6	-398.32	-281.85	-325.52	-353.91	-376.33
Comprehensive Income & Other	-24.36	-26.58	-7.96	-2.38	-2.16	-
Total Common Equity	786.6	817.67	940.96	702.86	887.54	704.57
Minority Interest	26.05	28.84	15.81	28.4	55.91	-
Shareholders' Equity	812.65	846.51	956.77	731.27	943.45	704.57
Total Liabilities & Equity	870.04	912.7	1,050	821.82	1,024	725.34
Total Debt	8.52	9.43	13.09	15.77	4.42	-
Net Cash (Debt)	576.83	609.59	711.18	477.64	684.86	513.03
Net Cash Growth	-14.37%	-14.28%	48.90%	-30.26%	33.49%	38.74%
Net Cash Per Share	4.68	4.95	5.91	4.63	6.76	5.87
Filing Date Shares Outstanding	124.26	124.26	123.08	103.08	103.08	92
Total Common Shares Outstanding	124.26	124.26	123.08	103.08	103.08	92
Working Capital	659.66	684.47	754.93	510.03	709.42	528.47
Book Value Per Share	6.33	6.58	7.65	6.82	8.61	7.66
Tangible Book Value	666.12	686.51	772.83	474.82	608.52	602.28
Tangible Book Value Per Share	5.36	5.52	6.28	4.61	5.90	6.55
Machinery	31.6	31.6	31.19	24.66	24.55	23.87
Construction In Progress	-	-	37.57	14.91	-	-
Leasehold Improvements	38.15	38.15	0.34	0.34	0.34	3.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.